Keyword | CPC | PCC | Volume | Score | Length of keyword |
---|---|---|---|---|---|
nivolumab melanoma approval | 0.76 | 0.3 | 1573 | 29 | 27 |
nivolumab | 1.28 | 0.3 | 2758 | 71 | 9 |
melanoma | 0.26 | 0.6 | 1998 | 52 | 8 |
approval | 0.42 | 0.7 | 9697 | 77 | 8 |
Keyword | CPC | PCC | Volume | Score |
---|---|---|---|---|
nivolumab melanoma approval | 0.59 | 0.9 | 6827 | 100 |
nivolumab fda approval melanoma | 0.08 | 1 | 6294 | 8 |
relatlimab nivolumab melanoma fda approval | 1.43 | 0.2 | 2266 | 97 |
fda approval of nivolumab | 0.94 | 0.7 | 7111 | 48 |
nivolumab for metastatic melanoma | 1.63 | 0.2 | 318 | 78 |
nivolumab immunotherapy for melanoma | 1.99 | 0.2 | 8254 | 31 |
nivolumab fda approval date | 1.78 | 0.7 | 2932 | 100 |
nivolumab fda approval history | 0.03 | 0.5 | 4710 | 53 |
nivolumab fda approval nsclc | 1.88 | 0.8 | 8663 | 37 |
nivolumab and ipilimumab melanoma | 1.91 | 0.8 | 3160 | 99 |
when was nivolumab fda approved | 1.61 | 0.2 | 4476 | 85 |
nivolumab and pembrolizumab for melanoma | 0.7 | 1 | 9181 | 94 |
monoclonal antibody melanoma nivolumab | 2 | 0.9 | 6015 | 6 |
nivolumab fda approved indications | 0.98 | 0.4 | 4581 | 7 |
nivolumab pancreatic cancer fda approval | 0.39 | 0.3 | 141 | 14 |